Genzyme Corp. (GENZ) Presents Positive Results from Alemtuzumab Phase 2 In Patients With MS
Tweet Send to a Friend
Genzyme Corporation (Nasdaq: GENZ) updates on patient data in a five-year MS Phase 2 trial.
This sub-group analysis found ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This sub-group analysis found ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
